

OBESITY DRUGS AND THERAPIES: TECHNOLOGIES AND GLOBAL MARKETS



HLC188A
May 2016

Kim Lawson
Project Analyst

ISBN: 1-62296-289-3



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOAL AND OBJECTIVES	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
WHERE PROGRESS WAS	7
<i>SUMMARY TABLE GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	9
<i>SUMMARY FIGURE GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, 2014-2021 (\$ MILLIONS)</i>	9
KEY DRIVERS	11
KEY CHALLENGES	11
KEY TRENDS	12
CHAPTER 3 OBESITY OVERVIEW AND BACKGROUND	14
<i>TABLE 1 BMI CATEGORIES</i>	14
OBESITY EXPLAINED	15
<i>TABLE 2 KEY ADIPOCYTOKINES AND MAIN EFFECTS</i>	16
BIOCHEMISTRY INVOLVED IN OBESITY	17
<i>FIGURE 1 MAIN SIGNALING AREAS TARGETED FOR OBESITY INTERVENTION</i>	19
Neuropeptide Y (NPY) Inhibitors	19
Sympathomimetics	20
Tesofensine	20
Dopamine Antagonists	20
Cannabinoid-1 Receptor (CB1) Antagonists	21
Leptin	21
Bupropion	22
Zonisamide	22
Gastrointestinal Areas of Activity	23
Glucagon-like Peptide-1 Analogues	23
Monoacylglycerol Acyltransferase 2 (MGAT2)-Mediated Enzyme	24
Oxyntomodulin	24
PYY	25
CCK and CCK1R Agonists	25
Ghrelin and Ghrelin Inhibitors	25
Enterostatin and Apolipoprotein A-IV	25
Pancreatic Polypeptide (PP)	26
Amylin and Amylin Analogues	26
Lipase Inhibitors	26

TOPIC	PAGE NO.
Cyclic Nucleotides	27
OBESITY CAUSES	27
Age	27
Genetics	27
Pregnancy	28
Medications	28
Inadequate or Excessive Sleep	28
RELATED CONDITIONS	28
Polycystic Ovary Syndrome (PCOS)	28
Cardiovascular Disease	29
Cancer	29
Binge Eating	30
TABLE 3 MEDICATIONS IN DEVELOPMENT FOR BINGE EATING	30
Diabetes	31
Standard Diabetic Treatments	32
Metformin	32
Sulfonylurea (SU)	33
Thiazolidinedione (TZD)	33
Alpha-Glucosidase Inhibitors	34
Insulin Treatment	34
Long-Acting Insulin	34
Intermediate-Acting Insulin	35
Regular or Short-Acting Insulin	35
Rapid-Acting Insulin	35
FIGURE 2 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014	35
Incretin Therapies	36
TABLE 4 COMMERCIALIZED INCRETIN THERAPY	38
TABLE 5 ADVANTAGES TO ADDING INCRETIN THERAPY	39
Exenatide	39
Liraglutide	41
Dulaglutide	42
Albiglutide	43
Lixisenatide	43
DATA ON INCRETIN USE	44
FIGURE 3 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)	44
GLP-1's Future in Obesity	45
TABLE 6 GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT	46
TABLE 7 GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT	46
CHAPTER 4 MARKET OVERVIEW AND FORECAST	49
OVERALL PHARMA MARKET	49
TABLE 8 REVENUE OF TOP PHARMA COMPANIES, 2014 (\$ BILLIONS)	49
FIGURE 4 GLOBAL MARKET SHARE OF PHARMACEUTICAL DRUGS BY REGION, 2014 AND 2019	50
DIABETES AS SALES TERRITORY	51
BIOLOGICS AND GLP-1 RECEPTOR AGONIST PRODUCTION	52
GROWTH FACTORS	54

TOPIC	PAGE NO.
GENE THERAPY	54
RECOMBINANT PROTEINS	54
MONOCLONAL ANTIBODIES	54
BIOLOGIC LANDSCAPE	54
<i>TABLE 9 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013</i>	55
OBESITY TREATMENTS WITHIN THE PHARMA LANDSCAPE	55
MARKET LANDSCAPE	56
DEALS IN THE OBESITY MARKET	57
<i>TABLE 10 KEY AGREEMENTS AROUND OBESITY TREATMENTS</i>	58
BRIEF HISTORY OF OBESITY DRUGS	61
RECENT TRENDS AND OBESITY THERAPY APPROVALS	61
<i>TABLE 11 TIMELINE OF OBESITY MEDICATION APPROVALS</i>	62
FDA-APPROVED ANTI-OBESITY MEDICATIONS DESCRIBED	63
Desoxyephedrine	63
Phendimetrazine	63
Benzphetamine	63
Diethylpropion	64
Orlistat (Xenical)	64
Phentermine and Topiramate Extended-Release (Qsymia)	64
Lorcaserin Hydrochloride (Belviq)	65
Naltrexone and Bupropion Extended-Release Tablets (Contrave/Mysimba)	66
Liraglutide (Saxenda)	67
Cetilistat (Oblean-Approved in Japan Only)	68
<i>TABLE 12 FDA-APPROVED LONGER-TERM ANTI-OBESITY MEDICATIONS' MECHANISM OF ACTION AND WEIGHT-LOSS STATISTICS IN CLINICAL TRIALS</i>	69
<i>FIGURE 5 NUMBER OF COMMERCIALIZED OBESITY DRUGS AND DEVICE THERAPEUTICS, 2016 AND 2021 (UNITS)</i>	70
<i>FIGURE 6 NUMBER OF COMMERCIALIZED BARIATRIC SURGERIES MINUS BANDS AND BALLOONS, 2016 AND 2021 (UNITS)</i>	71
<i>FIGURE 7 NUMBER OF COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)</i>	72
<i>FIGURE 8 GLOBAL MARKET FOR COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)</i>	72
<i>FIGURE 9 NUMBER OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)</i>	74
<i>FIGURE 10 GLOBAL MARKET OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)</i>	75
WEIGHT LOSS THROUGH SURGERY	76
Gastric Bypass	76
Biliopancreatic Diversion with Duodenal Switch (BPD/DS) Gastric Bypass	76
Sleeve Gastrectomy	77
Adjustable Gastric Band	77
SURGERY OUTCOMES	78
<i>TABLE 13 PROS AND CONS OF BARIATRIC SURGERY</i>	79
<i>FIGURE 11 FOUR MOST COMMON U.S. BARIATRIC PROCEDURES</i>	79
<i>TABLE 14 DIFFERENCES BETWEEN THE OBESITY SURGERIES</i>	81

TOPIC	PAGE NO.
ACCESS TO WEIGHT-LOSS SURGERY	82
<i>FIGURE 12 CASE MIX OF BARIATRIC SURGERIES IN THE U.S., 2014 (%)</i>	84
GASTRIC BANDS AND BALLOONS DETAILED	85
<i>TABLE 15 TIMELINE OF OBESITY DEVICE APPROVALS</i>	85
Lap-Band Gastric Banding System	85
Realize Gastric Band	86
Maestro Rechargeable System	86
<i>FIGURE 13 MAESTRO RECHARGEABLE SYSTEM</i>	87
BALLOONS AS PART OF BANDS	88
ReShape Integrated Dual Balloon System	89
ORBERA Intra-gastric Balloon System	89
<i>FIGURE 14 NUMBER OF COMMERCIALIZED OBESITY DEVICES*, 2016 AND 2021 (%)</i>	90
SURGICAL USAGE AND SPENDING	91
<i>TABLE 16 BARIATRIC SURGERY SPENDING IN EUROPE, 2012</i>	91
CHAPTER 5 DEVELOPMENT PIPELINE DETAILED	94
DEVICE APPROVAL PROCESS	94
BENEFIT/RISK MODEL FOR FDA CLINICAL TRIALS	94
<i>TABLE 17 FDA BENEFIT-RISK ASSESSMENT FOR OBESITY DEVICE CLINICAL TRIALS</i>	95
<i>TABLE 18 TARGET EFFECTIVENESS LEVELS FOR TOTAL BODY WEIGHT LOST (TBL) (%)</i>	97
MOVING OBESITY DRUGS THROUGH THE FDA	97
PATENTS	98
DEVELOPMENT PIPELINE	100
<i>TABLE 19 OBESITY DRUGS IN DEVELOPMENT</i>	100
KEY OBESITY DRUGS IN DEVELOPMENT	101
ZGN-440 (Beloranib)	101
Setmelanotide (RM-493)	102
Semaglutide (NN9536-GLP-1 Analogue)	102
HM11260C/Efpeglenatide (Glucagon-like Peptide-1 Analogue)	103
LAPSGLP/GCG-HM12525A (Glucagon-like Peptide-1 Analogue/Glucagon Analogue)	103
ALS L1023 (Korean Clinical Trial)	103
ZP2929	104
PL-8905	104
Merck and NGM Biopharmaceuticals and NGM313, NGM386 and NGM395	105
MOD-6031 (Long-Acting Oxyntomodulin)	105
Tesofensine	106
Gelesis100	106
OBESITY DEVICES IN DEVELOPMENT	108
Obalon Therapeutics' Obalon balloon	108
Aspire Bariatrics' AspireAssist	108
SatiSphere System	109
Sensor Monitored Alimentary Restriction Therapy (SMART)	110
Spatz3 Adjustable Balloon	110
OTHER DEVICES	111
GI Dyamics' EndoBarrier	111

TOPIC	PAGE NO.
Allurion Technologies' Elipse Gastric Balloon	111
MetaCure's Diamond System	111
BAROnova's TransPyloric Shuttle (TPS)	112
DEVELOPMENT CASE STUDY: ZAFGEN	113
PROMISING NOVEL RESEARCH	114
OBESITY DRUGS IN EARLY RESEARCH	114
SYM401	114
Glycine-Beta Muricholic Acid (Gly-MCA)	115
Metformin	115
Miglitol	115
Fibroblast Growth Factor 21 (FGF21)	116
Amlexanox	116
p75 Neurotrophin Receptor (NTR)	116
Transcranial Direct Current Stimulation	117
Perforin and Dendritic Cells	117
<i>TABLE 20 OBESITY DRUG AND DEVICE DEVELOPMENT RESOURCES</i>	117
CHAPTER 6 COMPANY PROFILES	121
ALLURION TECHNOLOGIES	121
A.M.I. GMBH AUSTRIA	121
AMUNIX	122
APOLLO ENDOSURGERY INC.	123
ARENA PHARMACEUTICALS INC.	124
ARISAPH	125
ASPIRE BARIATRICS INC.	126
ASTRAZENECA	127
ATHERSYS INC.	127
BARONOVA INC.	128
BECTON, DICKINSON AND CO.	128
BFKW	128
BOEHRINGER INGELHEIM GMBH	129
BRISTOL-MYERS SQUIBB	130
CIRCUIT THERAPEUTICS INC.	131
CONJUCHEM	131
C.R. BARD INC.	132
DONG-A SOCIO HOLDINGS	132
EISAI	133
ELI LILLY AND CO.	133
EMISPHERE TECHNOLOGIES INC.	134
ENDOBETIX	136
ENDOSPHERE INC.	136
ENTEROMEDICS INC.	137
ETHICON ENDO-SURGERY LLC	138
GELESIS INC.	139
GI DYNAMICS INC.	140
GLAXOSMITHKLINE PLC	141
HANMI PHARMACEUTICAL CO. LTD.	142

TOPIC	PAGE NO.
HELIOSCOPE	143
INTARCIA THERAPEUTICS INC.	144
INTRAPACE INC.	145
INTREXON CORP.	145
JOHNSON & JOHNSON	146
LIGAND PHARMACEUTICALS INC.	147
LIGHTLAKE THERAPEUTICS INC.	147
MANNKIND CORP.	148
MEDTRONIC	149
MERCK	149
MERRION PHARMACEUTICALS LTD.	151
METACURE GERMANY GMBH	152
MID-MEDICAL INNOVATION DEVELOPMENT	152
mitsubishi tanabe pharma corp.	153
NEOTHETICS INC.	154
NGM BIOPHARMACEUTICALS INC.	155
NORGINE B.V.	155
NOVARTIS INTERNATIONAL AG	156
NOVO NORDISK A/S	156
OBALON THERAPEUTICS	158
ONCIOMED	159
ONO PHARMACEUTICALS	159
OPKO BIOLOGICS	160
ORAMED PHARMACEUTICALS	161
OREXIGEN	161
PALATIN TECHNOLOGIES INC.	163
PFIZER	163
PHASEBIO PHARMACEUTICALS INC.	165
PLENSAT INC.	165
RESHAPE MEDICAL INC.	166
RHYTHM	166
ROCHE	167
SANIONA	168
SANOFI	169
SATRX LLC	170
SCIENTIFIC INTAKE	171
SHIRE PHARMACEUTICALS INC.	171
SPATZ FGIA	172
SYMMETRY THERAPEUTICS INC.	173
TAKEDA PHARMACEUTICAL CO. LTD.	173
TRANSITION THERAPEUTICS INC.	174
TULIP MEDICAL	175
VALENTX	176
VIVUS INC.	176
VTV THERAPEUTICS INC.	178
W.L. GORE AND ASSOCIATES	178
ZAFGEN	179

TOPIC	PAGE NO.
ZEALAND PHARMA A/S	180
ZOSANO PHARMA CORP.	181

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, THROUGH 2021 (\$ MILLIONS)	9
TABLE 1 BMI CATEGORIES	14
TABLE 2 KEY ADIPOCYTOKINES AND MAIN EFFECTS	16
TABLE 3 MEDICATIONS IN DEVELOPMENT FOR BINGE EATING	30
TABLE 4 COMMERCIALIZED INCRETIN THERAPY	38
TABLE 5 ADVANTAGES TO ADDING INCRETIN THERAPY	39
TABLE 6 GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT	46
TABLE 7 GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT	46
TABLE 8 REVENUE OF TOP PHARMA COMPANIES, 2014 (\$ BILLIONS)	49
TABLE 9 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013	55
TABLE 10 KEY AGREEMENTS AROUND OBESITY TREATMENTS	58
TABLE 11 TIMELINE OF OBESITY MEDICATION APPROVALS	62
TABLE 12 FDA-APPROVED LONGER-TERM ANTI-OBESITY MEDICATIONS' MECHANISM OF ACTION AND WEIGHT-LOSS STATISTICS IN CLINICAL TRIALS	69
TABLE 13 PROS AND CONS OF BARIATRIC SURGERY	79
TABLE 14 DIFFERENCES BETWEEN THE OBESITY SURGERIES	81
TABLE 15 TIMELINE OF OBESITY DEVICE APPROVALS	85
TABLE 16 BARIATRIC SURGERY SPENDING IN EUROPE, 2012	91
TABLE 17 FDA BENEFIT-RISK ASSESSMENT FOR OBESITY DEVICE CLINICAL TRIALS	95
TABLE 18 TARGET EFFECTIVENESS LEVELS FOR TOTAL BODY WEIGHT LOST (TBL) (%)	97
TABLE 19 OBESITY DRUGS IN DEVELOPMENT	100
TABLE 20 OBESITY DRUG AND DEVICE DEVELOPMENT RESOURCES	117

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, 2014-2021 (\$ MILLIONS)	9
FIGURE 1 MAIN SIGNALING AREAS TARGETED FOR OBESITY INTERVENTION	19
FIGURE 2 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014	35
FIGURE 3 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)	44
FIGURE 4 GLOBAL MARKET SHARE OF PHARMACEUTICAL DRUGS BY REGION, 2014 AND 2019	50
FIGURE 5 NUMBER OF COMMERCIALIZED OBESITY DRUGS AND DEVICE THERAPEUTICS, 2016 AND 2021 (UNITS)	70
FIGURE 6 NUMBER OF COMMERCIALIZED BARIATRIC SURGERIES MINUS BANDS AND BALLOONS, 2016 AND 2021 (UNITS)	71
FIGURE 7 NUMBER OF COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)	72
FIGURE 8 GLOBAL MARKET FOR COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)	72
FIGURE 9 NUMBER OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)	74
FIGURE 10 GLOBAL MARKET OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)	75
FIGURE 11 FOUR MOST COMMON U.S. BARIATRIC PROCEDURES	79
FIGURE 12 CASE MIX OF BARIATRIC SURGERIES IN THE U.S., 2014 (%)	84
FIGURE 13 MAESTRO RECHARGEABLE SYSTEM	87
FIGURE 14 NUMBER OF COMMERCIALIZED OBESITY DEVICES*, 2016 AND 2021 (%)	90